This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	p21 Protein (Cdc42 Rac)-activated kinase 4 (PAK4)	<p><i>In vitro</i> and rodent studies identified a pyrroloaminopyrazole series of PAK4 inhibitors that could help treat cancers. Alkyl amides from the series had potent activity against the kinase <i>in vitro</i> and had favorable oral bioavailability in rats. In mice with human melanoma and colon cancer PAK4-driven xenografts, two of the compounds decreased tumor volume compared with no treatment. Next steps could include testing the inhibitors in additional animal models.</p> <p>SciBX 5(21); doi:10.1038/scibx.2012.544 Published online May 24, 2012</p>	Patent and licensing status unavailable	<p>Guo, C. <i>et al. J. Med. Chem.</i>; published online May 3, 2012; doi:10.1021/jm300204j Contact: Chuangxing Guo, Pfizer Global Research and Development, San Diego, Calif. e-mail: alexguo01@gmail.com Contact: Indrawan McAlpine, same affiliation as above e-mail: indrawan.mcalpine@pfizer.com</p>